SEC Tracker
Get the app

Transcode Therapeutics RNAZ

TransCode initiates strategic review

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Board initiated strategic process to evaluate value opportunities
  2. Focus on oncology portfolio and lead product TTX-MC138

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Transcode Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  2. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  3. Vyome Holdings HIND public float $6M, Jun 30, 2025
  4. Biomerica BMRA public float $7M, Nov 28, 2025
  5. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025